ExSight Ventures

Partners Randolph Cohen and Firas Rahhal — both fellowship-trained retinal surgeons — lead the firm's investing. The firm's website frames their clinical expertise as the core of its deal selection and portfolio-company support model. No additional investment professionals are named publicly.

The firm leans on the partners' direct clinical networks and academic ophthalmology relationships. As practicing surgeons, Cohen and Rahhal maintain contact with leading researchers, innovators, and strategic acquirers in the eye-care field. ExSight argues this gives it access to early-stage opportunities that generalist healthcare investors miss.

ExSight operates as a specialized, returns-oriented venture capital firm, not a family office. It manages outside limited-partner capital and invests solely in ophthalmology. The firm explicitly distinguishes itself from large, multi-sector healthcare VC platforms.

The firm invests from pre-seed through Series B, concentrating where its capital can have outsized impact on company formation. ExSight states that most of its investment dollars go toward technology development rather than sales and marketing at this stage, which it views as a capital-efficient approach.

No. The firm's entire mandate is ophthalmic diagnostics, devices, drugs, and software. It publicly argues that specialization — not diversification within a single manager — drives superior risk-adjusted returns, and its portfolio reflects an ophthalmology-only commitment.